Shares of OptimizeRx surged 13.9% in after-hours trading to $5.58 on June 25 after a one-two punch: a reiterated Market Outperform rating from Citizens with a $9.00 price target, and the launch of a new AI-powered tool that lets pharma marketers build custom doctor audiences using plain-language queries. The stock had already climbed from $4.54 to $4.90 over four sessions. The question for shareholders is whether fresh products and Wall Street backing can reverse a painful revenue slide.
A $9 Target Sounds Bullish — Until You See How Far Estimates Have Fallen Citizens' $9 target implies roughly 61% upside from the current after-hours price, and the average analyst target across eight firms sits at $9.19, with a range from $5 to $16. But the optimism comes against a grim backdrop: the company trimmed its 2026 revenue outlook to $95–$100 million, down from the prior $109–$114 million range.
Consensus among seven analysts is now $97 million, a 9.2% year-over-year decline. The bull case rests on future growth, not current trajectory.
The New AI Tool Targets a Big Untapped Channel
The company launched a patent-pending AI tool designed to be embedded within advertising-buying platforms used by pharma agencies.
It combines real-world medical evidence with data from OptimizeRx's network of electronic health records so marketers can build custom doctor audiences inside their existing workflows. CEO Stephen Silvestro called programmatic ad buying — where software automatically places ads — "an important growth channel," noting it could "create new recurring revenue streams for our business." The tool goes live for integration in August 2026.
Revenue Is Down, but Margins Are Up — A Tricky Signal
Q1 revenue fell 10% year-over-year to $19.8 million, but EPS came in at $0.14 (up from $0.08) and adjusted EBITDA — a rough measure of cash profits — jumped 120% to $3.3 million.
The company's AI-driven targeting platform grew 60%, with related subscription revenues up 45%. Management is holding its profit outlook of $21–$25 million in adjusted EBITDA for 2026, even as it cuts the top line. That suggests aggressive cost-cutting is masking demand weakness.
The Stock Is Cheap for a Reason
OPRX trades at a forward price-to-sales ratio of just 0.84, far below the sector's 6.94.
Management admits it's using less than 10% of its available ad inventory — a massive gap between potential and reality. If programmatic channels and the new AI tool can close even a fraction of that gap, the upside is significant. If not, the cheap valuation simply reflects a company whose biggest customers are pulling back spending.